The Final Rule was mooted for implementation over a staged transition period, determined by a service’s risk level, by 2028.

Natera has announced findings from a study evaluating its Signatera in individuals with soft tissue and bone sarcomas.

Firefly Neuroscience has completed the acquisition of Evoke Neuroscience, a developer of technologies aimed at assessing ...

URA has entered the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s CGM ...

InBrain Neuroelectronics has won a €4m ($4.5m) grant from the Spanish Ministry of Industry and Tourism to develop its BCI ...

Zimmer Biomet has adjusted its 2025 earnings forecast to $7.90-$8.10 per share, down from previous estimates falling between ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to GE HealthCare's Aurora nuclear medicine system and ...

Tariffs, though designed as economic tools, have ripple effects that extend deeply into the regulatory framework of the ...

Core has completed the acquisition of neurotechnology solution provider NeuroMetrix, including its Quell platform.

The FDA designation is a step forward for Neuralink as owner Elon Musk faces increasing scrutiny. The US Food and Drug ...

Neurogen Biomarking has announced a collaboration with NeuroX to support patients’ journey on its brain health care ecosystem ...

The FDA has approved Edwards Lifesciences' SAPIEN 3 TAVR platform for the treatment of patients with asymptomatic severe ...